opzelura.com — September 2026 traffic, keywords & AI visibility

Search engines send opzelura.com an estimated 27,300 visits a month. Effectively all of it is organic — about 27,300 visits from unpaid results. Paid search contributes only about 18 visits a month. Spread across 507 ranking keywords, that averages roughly 54 organic visits per keyword.

opzelura.com scores 67 out of 100 on our AI visibility scale, grade C. It takes full marks for LLMS.txt and Structured data. The biggest gap is SEO health, at 0 of 20 points (0/100), worth 20 points if closed. It also loses points on Crawlability (0/10) and Company profile (22/25).

The llms.txt on opzelura.com runs to 73 lines (4,424 characters) across 12 sections, last generated in May 2026. It introduces the site as "Opzelura". It tells AI engines the business works in Healthcare, Life Sciences & Wellness; Pharmaceuticals; and Dermatology. It describes 1 product, including Opzelura Cream. Services it lists include Patient Support Program, Prescribing Information and Medication Guide. The audience it names is Patients with inflammatory skin conditions, aged Adults and adolescents (Global). The keywords it claims start with "atopic dermatitis", "vitiligo", "ruxolitinib" and "topical cream". It gives the company type as Public.

# Opzelura

## About
Opzelura is a prescription topical cream developed to help patients manage the symptoms of atopic dermatitis and non-segmental vitiligo. The medication is formulated with ruxolitinib, a JAK inhibitor that works directly on the skin to reduce inflammation and support repigmentation. Patients apply the cream twice daily to affected areas, and clinical studies have shown meaningful improvement in itch and skin appearance within weeks. The treatment is positioned for people who have not responded well to topical steroids or other standard therapies. Opzelura is marketed through a network of dermatology specialists and is supported by patient assistance programs that help with access and affordability. The company behind Opzelura, Incyte, has a long track record in developing targeted therapies for blood cancers and inflammatory conditions. Opzelura represents the first topical JAK inhibitor approved by the FDA for these specific skin conditions. The product is available by prescription only and comes with detailed safety information and monitoring guidelines. Opzelura’s development involved extensive clinical trials across multiple countries to establish both safety and efficacy. The brand maintains a dedicated website that provides prescribing information, medication guides, and resources for both patients and healthcare providers. Opzelura is also supported b

Google lists opzelura.com for about 507 keywords, which together bring an estimated 27,300 organic visits a month.

The latest technical audit of opzelura.com scored 0 out of 100 overall. The audit makes 8 recommendations in all.

Opzelura's company profile names https://www.opzeluraontrac.com/, https://opzelura.pregnancy.incyte.com/, https://incyte.com/ and https://www.opzelurahcp.com/ as competitors. Its own llms.txt adds https://www.examplecompetitor1.com/ and https://www.examplecompetitor2.com/. Outside its market, the domains ranked closest to it in our worldwide ranking are mini.nl, barangaroo.com, nrcm.org and pko-astana.kz.

https://www.opzeluraontrac.com/

https://opzelura.pregnancy.incyte.com/

https://incyte.com/

https://www.opzelurahcp.com/

https://www.examplecompetitor1.com/

https://www.examplecompetitor2.com/